Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results